AveXis Announces Proposed Public Offering of Common Stock
June 19 2017 - 4:00PM
AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer
and sell, subject to market conditions, up to $200 million of
shares of its common stock in an underwritten public offering. The
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
Goldman Sachs & Co. LLC, Jefferies LLC and BofA Merrill
Lynch are acting as joint book-running managers. BMO Capital
Markets Corp. is acting as lead manager and Chardan is acting as
co-manager of the offering. AveXis intends to grant the
underwriters a 30-day option to purchase up to an additional $30
million of shares of common stock at the public offering price,
less the underwriting discounts and commissions.
The offering will be made pursuant to a shelf registration
statement on Form S-3 that was filed by AveXis with the Securities
and Exchange Commission (“SEC”) and became automatically effective
on March 17, 2017. The offering will be made only by means of
a written prospectus and prospectus supplement that form a part of
the registration statement. A preliminary prospectus
supplement and accompanying prospectus relating to and describing
the terms of the offering will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov. When
available, copies of the preliminary prospectus supplement and
accompanying prospectus may also be obtained for free from the
offices of Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, NY 10282; by telephone at
1-866-471-2526; or by email at prospectus-ny@ny.email.gs.com,
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022; by phone at
1-877-821-7388; or by email at Prospectus_Department@Jefferies.com,
or BofA Merrill Lynch at NC1-004-03-43, 200 North College Street,
3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus
Department or by email at dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy any of these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the applicable
securities laws of such state or jurisdiction.
About AveXis, Inc.AveXis is a clinical-stage
gene therapy company developing treatments for patients suffering
from rare and life-threatening neurological genetic diseases. The
company’s initial proprietary gene therapy candidate, AVXS-101, is
in an ongoing Phase 1 clinical trial for the treatment of SMA Type
1.
Media Inquiries:
Lauren Barbiero
W2O Group
646-564-2156
lbarbiero@w2ogroup.com
Investor Inquiries:
Jim Goff
AveXis, Inc.
650-862-4134
jgoff@avexis.com
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jul 2024 to Aug 2024
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Aug 2023 to Aug 2024